# A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)

> **NIH NIH R21** · CYANVAC, LLC · 2024 · $201,900

## Abstract

ABSTRACT
In this R21 application, we propose to develop a universal, intranasal, parainfluenza virus 5 (PIV5)-based
respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) bivalent vaccine. RSV and HMPV are
two of the leading causes of acute respiratory infections (ARIs) in children, immunocompromised individuals,
and the elderly. Illness ranges from asymptomatic infection to severe bronchiolitis and pneumonia, with 90-100%
of children infected with RSV by 2 years of age, and HMPV between the ages of 5-10 years old. No licensed
RSV or HMPV vaccine is available and there is an unmet medical need to develop safe and effective vaccines
for both diseases. A recent proof-of-principle study has shown that it is possible to create a chimeric F protein
(RHMS-1) by combining immunodominant epitopes from RSV F and HMPV F that retains antigenicity for both
viruses, the purified protein is immunogenic and protective against RSV and HMPV challenge in mice. However,
this purified protein requires an adjuvant and a multi-dose approach, the cell-mediated immune response was
not studied, the duration of the antibody response has not been determined, and there is a potential safety
concern for children due to the high dose of protein required for the vaccine to be immunogenic. PIV5 is a safe
delivery vector for intranasal immunization. A PIV5-vectored RSV candidate vaccine (BLB-201) has already been
cleared by the FDA for a phase I clinical trial this year (NCT05281263). Due to the similarities between RSV and
HMPV F proteins, disease manifestation, and target populations, a bivalent vaccine is desirable to protect against
ARI diseases caused by both viruses. Here, we propose to introduce the RHMS-1 novel sequence into the PIV5-
vectored vaccine platform. We will also make a modification to the RHMS-1 sequence to improve F protein
expression and its immunogenicity. The constructs to be evaluated include: 1) RHMS-1 pre-fusion; and 2)
RHMS-1 pre-fusion form with the trimerization domain replaced with the transmembrane domain and cytoplasmic
tail from the PIV5 F protein. The candidate vaccine viruses will be compared for their replication and antigen
expression in vitro, and immunogenicity and protective efficacy against RSV and HMPV challenge infection in
vivo. The novelty of the vaccine proposed in this R21 application relates to: 1) the use of a chimeric RSV+HMPV
F protein against two pathogens (bivalent vaccine); 2) a needle-free intranasal delivery method in a safe, highly
immunogenic viral vector; 3) ease of administration; and 4) the ability to induce cellular and antibody responses
including mucosal immunity, which is necessary for protecting against respiratory pathogens. The project is very
promising in generating an effective bivalent vaccine that could provide protection against the two leading causes
of acute lower respiratory tract infections in children and older adults.

## Key facts

- **NIH application ID:** 10920481
- **Project number:** 5R21AI175677-02
- **Recipient organization:** CYANVAC, LLC
- **Principal Investigator:** Maria Cristina Gingerich
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $201,900
- **Award type:** 5
- **Project period:** 2023-09-05 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10920481

## Citation

> US National Institutes of Health, RePORTER application 10920481, A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) (5R21AI175677-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10920481. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*